This segment focuses on the research, development, and commercialization of novel therapies for kidney diseases. Key activities include preclinical studies, clinical trials, and regulatory submissions for product candidates like Renazorb (for hyperphosphatemia) and UNI-494 (for acute kidney injury). The company utilizes advanced pharmaceutical technologies and methodologies to formulate and deliver these treatments, aiming to improve patient outcomes and quality of life for individuals suffering from chronic kidney disease and acute kidney injury. Market positioning is centered on addressing significant unmet medical needs in nephrology, with a competitive advantage derived from innovative drug development and intellectual property protection. Future opportunities include expanding the product pipeline and securing strategic partnerships to accelerate growth and market access. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships with Lotus Pharmaceuticals and other entities are crucial for market expansion and commercialization.